DENVER, April 29, 2010 (GLOBE NEWSWIRE) -- The law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that it has initiated its own investigation concerning losses suffered by certain XenoPort, Inc. investors (Nasdaq:XNPT).
The investigation relates to whether the company publicized misleading and incomplete information about its clinical trial program for Horizant (gabapentin enacarbil) as a treatment for Restless Leg Syndrome, including that there was strong evidence of safety and indicating that it remained on track. After the FDA recently denied approval of Horizant due to concerns about laboratory results showing pancreatic cell tumors in rats, XenoPort's stock price plummeted more than 60% to close at $6.67 per share on February 18, 2010.
If you purchased XenoPort common stock prior to February 18, 2010 or if you have information relevant to the investigation, you may contact Jeffrey A. Berens, Esq. at (888) 300-3362, (303) 861-1764 or via email at jeff@dyerberens.com.
The law firm of Dyer & Berens LLP focuses on complex litigation on behalf of injured investors throughout the nation. For more information about the firm, please go to www.DyerBerens.com.